These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
90. Clinical implications of angiotensin II type 1 receptor antibodies in antibody-mediated rejection without detectable donor-specific HLA antibodies after renal transplantation. Lee J; Park Y; Kim BS; Lee JG; Kim HJ; Kim YS; Huh KH Transplant Proc; 2015 Apr; 47(3):649-52. PubMed ID: 25891704 [TBL] [Abstract][Full Text] [Related]
91. Clinical Relevance of Donor-Specific IgM Antibodies in HLA Incompatible Renal Transplantation: A Retrospective Single-Center Study. Babu A; Andreou A; Briggs D; Krishnan N; Higgins R; Mitchell D; Barber T; Daga S Clin Transpl; 2016; 32():173-179. PubMed ID: 28564535 [TBL] [Abstract][Full Text] [Related]
92. Clinical relevance of pre- and post-transplant HLA antibodies, donor-specific, and nondonor-specific HLA antibodies detected by ELISA in renal transplantation. Lee PC; Chen YL; Wang WM; Tu WC; Chen HY Clin Transpl; 2013; ():385-91. PubMed ID: 25095533 [TBL] [Abstract][Full Text] [Related]
94. Impact of de novo donor-specific HLA antibodies detected by Luminex solid-phase assay after transplantation in a group of 88 consecutive living-donor renal transplantations. Dieplinger G; Ditt V; Arns W; Huppertz A; Kisner T; Hellmich M; Bauerfeind U; Stippel DL Transpl Int; 2014 Jan; 27(1):60-8. PubMed ID: 24131087 [TBL] [Abstract][Full Text] [Related]
95. Association of positive pre-transplant angiotensin II type 1 receptor antibodies with clinical outcomes in lung transplant recipients. Son BS; Lee HJ; Cho WH; So MW; Park JM; Yeo HJ Transpl Immunol; 2023 Oct; 80():101901. PubMed ID: 37442212 [TBL] [Abstract][Full Text] [Related]
96. Shared alloimmune responses against blood and transplant donors result in adverse clinical outcomes following blood transfusion post-renal transplantation. Hassan S; Regan F; Brown C; Harmer A; Anderson N; Beckwith H; Roufosse CA; Santos-Nunez E; Brookes P; Taube D; Willicombe M Am J Transplant; 2019 Jun; 19(6):1720-1729. PubMed ID: 30582278 [TBL] [Abstract][Full Text] [Related]
97. HLA Class II Antibodies at the Time of Kidney Transplantation and Cardiovascular Outcome: A Retrospective Cohort Study. Malfait T; Emonds MP; Daniëls L; Nagler EV; Van Biesen W; Van Laecke S Transplantation; 2020 Apr; 104(4):823-834. PubMed ID: 31369517 [TBL] [Abstract][Full Text] [Related]
98. Impact of persistent and cleared preformed HLA DSA on kidney transplant outcomes. Redondo-Pachón D; Pérez-Sáez MJ; Mir M; Gimeno J; Llinás L; García C; Hernández JJ; Yélamos J; Pascual J; Crespo M Hum Immunol; 2018 Jun; 79(6):424-431. PubMed ID: 29524568 [TBL] [Abstract][Full Text] [Related]
99. Clinical Relevance of Posttransplant DSAs in Patients Receiving Desensitization for HLA-incompatible Kidney Transplantation. Vo AA; Aubert O; Haas M; Huang E; Zhang X; Choi J; Peng A; Najjar R; Sethi S; Ammerman N; Lim K; Jordan SC Transplantation; 2019 Dec; 103(12):2666-2674. PubMed ID: 30883456 [TBL] [Abstract][Full Text] [Related]